Following positive Phase IIb trial results, RH5.1/Matrix-M has the potential to be the first blood-stage malaria vaccine brought to market.

Alumis has revealed encouraging results from a Phase I clinical trial of tyrosine kinase 2 (TYK2), A-005, in healthy subjects.

Novo Nordisk has announced positive results from its Phase III trial of CagriSema but fell short of a previously promised 25% weight loss.

Sorriso Pharmaceuticals announced that it is looking to move to Phase II after its ulcerative colitis treatment saw success over placebo.

Adicet Bio has dosed the first subject in a multicentre Phase I trial of ADI-270, a gamma delta CAR T-cell therapy for treating ccRCC.

Vertex said the Phase II trial met its primary endpoint, however there was only a minor difference to placebo.

As of 2005, 83% of babies with critical congenital heart defects were expected to live past one year, up from 67% in 1993.

Remedy Plan Therapeutics has commenced dosing in a randomised Phase I trial of hyperbolic NAMPT inhibitor, RPT1G, for cancers.

The WHO’s guidance provides direction on diversity and how to include patients who are pregnant, lactating and from low-middle income countries.

Immunocore has dosed the first subject in the Phase I/II trial of IMC-R117C for treating colorectal and other gastrointestinal cancers.

Tenya Therapeutics has said that its treatment for the heart condition was generally well tolerated despite some mild adverse events.

HighField has received clearance for its IND application from the CDE of China's NMPA to commence the Phase I trial of HF50.